Recce Pharmaceuticals Ltd
OTC: RECEF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James Hamilton-Bray Graham
- Headquarters
- Sydney, Australia
- IPO year
- 2022
- Market cap
- $80.4M
- Website
- https://www.recce.com.au
Loading RECEF…
Loading profile data…Frequently asked questions about RECEF
What does Recce Pharmaceuticals Ltd (RECEF) do?
Recce Pharmaceuticals Ltd is a biotechnology firm dedicated to the discovery, development, and commercialization of cutting-edge synthetic anti-infective treatments. The company's operations span major markets, including Australia, the United States, and the United Kingdom. Its primary drug candidate, RECCE 327, is engineered to combat severe bl...
Where does RECEF trade?
Recce Pharmaceuticals Ltd (RECEF) trades on the Other OTC.
What sector is RECEF in?
Recce Pharmaceuticals Ltd (RECEF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Recce Pharmaceuticals Ltd?
James Hamilton-Bray Graham is the chief executive officer of Recce Pharmaceuticals Ltd (RECEF).
Where is Recce Pharmaceuticals Ltd headquartered?
Recce Pharmaceuticals Ltd is headquartered in Australia.
Does RECEF pay a dividend?
Recce Pharmaceuticals Ltd (RECEF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RECEF go public?
Recce Pharmaceuticals Ltd (RECEF) completed its initial public offering in 2022.